Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 15/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25841514 | 0.89 | ENPP1 (0.38) | MAPK7ENPP1IRAK4 | |
| SCHEMBL20798023 | 0.86 | MAPK7 (0.50) | MAPK7ENPP1 | |
| SCHEMBL25841372 | 0.82 | ENPP1 (0.49) | MAPK7ENPP1IRAK4 | |
| SCHEMBL25841370 | 0.82 | ENPP1 (0.49) | MAPK7ENPP1IRAK4 | |
| SCHEMBL25841345 | 0.81 | ENPP1 (0.55) | ENPP1 | |
| SCHEMBL25841507 | 0.80 | IRAK4 (0.39) | MAPK7IRAK4 | |
| SCHEMBL25841511 | 0.78 | MAPK7 (0.37) | MAPK7IRAK4 | |
| SCHEMBL20798117 | 0.76 | ENPP1 (0.53) | MAPK7ENPP1 | |
| SCHEMBL29277814 | 0.75 | ENPP1 (0.52) | MAPK7ENPP1 | |
| SCHEMBL24067412 | 0.70 | ENPP1 (0.69) | MAPK7ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | MAPK7 2143/4885ENPP1 1/4885IRAK4 4130/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | MAPK7 2143/4885ENPP1 1/4885IRAK4 4130/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | MAPK7 2143/4885ENPP1 1/4885IRAK4 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.